Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5% – Time to Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price traded down 5% on Monday . The company traded as low as $87.57 and last traded at $86.5970. 43,076 shares changed hands during trading, a decline of 96% from the average daily volume of 1,112,356 shares. The stock had previously closed at $91.14.

Analysts Set New Price Targets

ORKA has been the topic of several research reports. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. UBS Group raised their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Guggenheim reissued a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Trading Down 0.1%

The stock has a market cap of $6.03 billion, a PE ratio of -44.85 and a beta of -0.34. The company’s 50 day moving average is $94.60 and its 200-day moving average is $67.75.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.33 EPS for the current year.

Insider Buying and Selling

In other news, SVP Arjun Agarwal sold 10,000 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at $3,659,181.12. This trade represents a 17.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 83,116 shares of company stock valued at $6,636,533. 23.49% of the stock is owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently modified their holdings of the company. Algert Global LLC lifted its holdings in Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares during the last quarter. Nykredit A S acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $29,000. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares in the last quarter. Kennedy Capital Management LLC grew its stake in Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after acquiring an additional 420 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.